Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
Phase 4
Not yet recruiting
- Conditions
- Mild Cognitive ImpairmentBiomarkerDiagnosisTreatment
- Interventions
- Drug: Placebo
- Registration Number
- NCT02931136
- Lead Sponsor
- Shanghai Mental Health Center
- Brief Summary
The purpose of this study is based on the Flutemetamol-PET senile plaque imaging to investigate the peripheral blood biochemical and brain MRI imaging biomarkers and to research completely independent intellectual property rights neuropsychological test tool for the MCI due to AD. At the same time, the investigators will study the efficacy and safety of early treatment of MCI due to AD by Huperzine A in 52 weeks.
- Detailed Description
This is a randmized, double-blind, placebo-controll study.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- memory complaint, preferably corroborated by a spouse or relative.
- objective memory impairment.
- normal general cognitive function.
- intact activities of daily living.
- absence of dementia.
- the positive of brain senile plaque.
Exclusion Criteria
- more than two lacuna ischemia (of diameter < 1 cm) as revealed by MRI fluid-attenuated inversion recovery (FLAIR) sequence.
- other type of dementia except AD
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo group Placebo The placebo in 52 weeks. treatment group Huperzine A Huperzine A treatment.
- Primary Outcome Measures
Name Time Method The average annual conversion rate in patients of MCI due to AD convert to the AD. 52 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Shanghai Mental Health Center
🇨🇳Shanghai, Shanghai, China